BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 14992966)

  • 1. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin.
    Onyike CU; Bonner JO; Lyketsos CG; Treisman GJ
    Am J Psychiatry; 2004 Mar; 161(3):429-35. PubMed ID: 14992966
    [No Abstract]   [Full Text] [Related]  

  • 2. Interferon for hepatitis C patients with psychiatric disorders.
    Wilson MS
    Am J Psychiatry; 2004 Dec; 161(12):2332; author reply 2332-4. PubMed ID: 15569921
    [No Abstract]   [Full Text] [Related]  

  • 3. Managing the neuropsychiatric complications of hepatitis C treatment.
    Sockalingam S; Shammi C; Stergiopoulos V
    Br J Hosp Med (Lond); 2007 Oct; 68(10):520-5. PubMed ID: 17974293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschr Med; 2002 Sep; 144(38):59. PubMed ID: 12395712
    [No Abstract]   [Full Text] [Related]  

  • 5. Psychosis during peginterferon-alpha 2a and ribavirin therapy: case report.
    Quarantini LC; Cruz SC; Batista-Neves SC; Paraná R; Miranda-Scippa A; Bressan RA
    Braz J Infect Dis; 2006 Dec; 10(6):406-7. PubMed ID: 17420915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peginterferon- and ribavirin-induced bipolar episode successfully treated with lamotrigine without discontinuation of antiviral therapy.
    Navinés R; Castellví P; Solà R; Martín-Santos R
    Gen Hosp Psychiatry; 2008; 30(4):387-9. PubMed ID: 18585548
    [No Abstract]   [Full Text] [Related]  

  • 7. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.
    Slim J; Afridi MS
    Infect Dis Clin North Am; 2012 Dec; 26(4):917-29. PubMed ID: 23083824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pegylated intereferon hematological safety in comparison with standard].
    Fazylov VKh; Manapova ÉR; Tkacheva SV; Sozinova IuM
    Eksp Klin Gastroenterol; 2012; (6):96-9. PubMed ID: 23402198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hepatitis C infection. Overweight virus carriers are more difficult to cure].
    MMW Fortschr Med; 2004 Mar; 146(13):58. PubMed ID: 15219135
    [No Abstract]   [Full Text] [Related]  

  • 10. [Side effects of interferon-based therapy for chronic hepatitis C virus infection and clinical management of them].
    Iwasaki Y; Ikeda F; Yamamoto K
    Nihon Rinsho; 2011 May; 69 Suppl 4():215-20. PubMed ID: 22096922
    [No Abstract]   [Full Text] [Related]  

  • 11. Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy.
    Jain S; Midha V; Sood A
    Indian J Gastroenterol; 2011 Sep; 30(5):239-40. PubMed ID: 21986854
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Summaries for patients. Duration and dose of antiviral treatment for chronic hepatitis C.
    Ann Intern Med; 2004 Mar; 140(5):I67. PubMed ID: 14996694
    [No Abstract]   [Full Text] [Related]  

  • 14. Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report.
    Verma P; Dayal S; Jain VK; Amrani A
    J Chemother; 2017 Dec; 29(6):380-382. PubMed ID: 27741937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with Peg interferon alfa-2a and ribavirin.
    Ennaifer R; Cheikh M; Romdhane H; Hefaiedh R; Ben Nejma H; Bel Hadj N
    Tunis Med; 2014 Jan; 92(1):42-3. PubMed ID: 24879173
    [No Abstract]   [Full Text] [Related]  

  • 16. Side effects of therapy for chronic hepatitis C.
    Russo MW; Fried MW
    Gastroenterology; 2003 May; 124(6):1711-9. PubMed ID: 12761728
    [No Abstract]   [Full Text] [Related]  

  • 17. A case of irreversible leukoencephalopathy in a patient with C virus hepatitis treated with pegylated interferon-alpha-2b and ribavirin.
    Iacob SA; Petrescu AM; Iacob DG
    Rom J Intern Med; 2013; 51(3-4):197-200. PubMed ID: 24620633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C.
    Sagir A; Wettstein M; Heintges T; Häussinger D
    Dig Dis Sci; 2002 Mar; 47(3):562-3. PubMed ID: 11911342
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antiviral therapy for chronic viral hepatitis B and C].
    Iino S
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():787-91. PubMed ID: 12722317
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.